MedTrace Logo

Evaluation in STEMI Patients Using FDY-5301

NCT04837001 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2351

Last updated 2025-09-12

No results posted yet for this study

Summary

To assess the effect of FDY-5301 on cardiovascular mortality and acute heart failure events in subjects with an anterior STEMI undergoing pPCI.

Conditions

  • Acute Myocardial Infarction
  • STEMI
  • Percutaneous Coronary Revascularization

Interventions

DRUG

FDY-5301

FDY-5301 will be administered as a single IV bolus injection.

OTHER

Placebo

Placebo will be administered as a single bolus injection.

Sponsors & Collaborators

  • Faraday Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-02
Primary Completion
2025-09-03
Completion
2025-09-03
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Hungary
  • Israel
  • Poland
  • Portugal

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04837001 on ClinicalTrials.gov